文献速递妇科

HUWE1/c-MYC通路异常使子宫颈癌对BET溴结构域抑制剂GS-626510敏感

Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.
PubMed 文献 · Gynecol Oncol · 2020-06-26

研究在23例宫颈癌标本中评估HUWE1/c-MYC表达,并在原代细胞系和CC-CVX8异种移植小鼠中测试新型BET抑制剂GS-626510的活性。结果显示新鲜冷冻宫颈癌和原代细胞系c-MYC过表达(p=.01),9/11(82%)原代细胞系FISH显示c-MYC扩增,HUWE1/c-MYC通路异常细胞系对GS-626510高度敏感。GS-626510每日两次口服耐受良好,显著抑制肿瘤生长(p=.004)并延长生存(p=.004)。

要点

  • 新鲜冷冻宫颈癌和原代细胞系较正常组织c-MYC过表达(p=.01)。
  • 9/11(82%)原代宫颈癌细胞系FISH显示c-MYC扩增。
  • GS-626510每日两次口服耐受良好,显著抑制CC-CVX8异种移植瘤生长并延长生存(均p=.004)。

核心结论

  • HUWE1下调/失活可能增加原代宫颈癌细胞系中c-MYC表达和增殖。
  • GS-626510可能是一种针对c-MYC过表达和/或携带HUWE1突变宫颈癌的新型、潜在高效治疗药物。
  • 作者认为,在携带放疗/化疗耐药疾病的宫颈癌患者中开展BET抑制剂临床研究是有必要的。

研究设计与样本

  • 研究评估新鲜冷冻宫颈癌和原代细胞系中HUWE1/c-MYC表达,并测试GS-626510对原代全外显子测序宫颈癌细胞培养和宫颈癌异种移植瘤的活性。
  • 用qRT-PCR评估23例宫颈癌(包括12例新鲜冷冻肿瘤组织和11例原代细胞系)中HUWE1和c-MYC表达。
  • 用蛋白质印迹和荧光原位杂交(FISH)在全部11例完成测序的原代宫颈癌细胞系中评估c-Myc表达。
  • 用增殖和活力检测评估原代肿瘤对GS-626510的体外敏感性,用siRNA实验评估HUWE1沉默对原代宫颈癌细胞系生长和GS-626510敏感性的影响。
  • 在CC-CVX8小鼠异种移植瘤中研究GS-626510的体内活性。

主要发现

  • 与正常组织相比,新鲜冷冻宫颈癌和原代宫颈癌细胞系c-MYC过表达(p=.01)。
  • FISH显示9/11(82%)原代宫颈癌细胞系存在c-MYC扩增。
  • HUWE1/c-MYC通路异常的细胞系对GS-626510高度敏感,细胞增殖和活力呈剂量依赖性下降。
  • siRNA沉默HUWE1显著增加c-MYC表达和宫颈癌细胞增殖,并增强对GS-626510的体外敏感性。
  • GS-626510每日两次口服在体内耐受良好,显著降低CC-CVX8异种移植瘤生长(p=.004)并提高生存(p=.004)。

临床怎么用

  • 作者认为,GS-626510可能是一种针对c-MYC过表达和/或携带HUWE1突变宫颈癌的新型、潜在高效治疗药物。
  • 作者认为,在携带放疗/化疗耐药疾病的宫颈癌患者中开展BET抑制剂临床研究是有必要的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Whole-exome-sequencing (WES) studies reported c-MYC gene-amplification and HUWE1 gene deletion/mutations in a significant number of cervical-cancer-patients (CC) suggesting HUWE1/c-MYC pathway as potential therapeutic target. We investigated HUWE1/c-MYC expression in fresh-frozen-CC and the activity of the novel BET inhibitor GS-626510 (Gilead-Science-Inc) against primary WES CC-cultures and CC-xenografts. METHODS: HUWE1 and c-MYC expression were evaluated by qRT-PCR in 23 CC including 12 fresh-frozen-tumor-tissues and 11 primary-cell-lines. c-Myc expression was also evaluated by Western-Blot (WB) and fluorescence-in-situ-hybridization (FISH) in all 11 fully sequenced primary-CC-cell-lines. Primary tumors were evaluated for sensitivity to GS-626510 in-vitro using proliferation and viability-assays. siRNA experiments were used to evaluate the effect of HUWE1 silencing on primary-CC-cell-line growth and sensitivity to GS-626510. Finally, the in-vivo activity of GS-626510 was studied in CC-CVX8-mouse-xenografts. RESULTS: Fresh-frozen-CC and primary-CC-cell-lines overexpressed c-MYC when compared to normal tissues (p = .01). FISH demonstrated amplification of c-MYC in 9/11 (82%) of the primary-CC-cell-lines. Cell-lines with derangements in HUWE1/c-MYC pathway were highly sensitive to GS-626510, with a dose-response decrease in cell proliferation and viability. siRNA silencing of HUWE1 significantly increased c-MYC expression and CC cell-proliferation and enhanced the in-vitro sensitivity to GS-626510. Twice-daily oral doses of GS-626510 were well tolerated in-vivo and highly effective in decreasing tumor-growth (p = .004) and increasing survival (p = .004) of CC-CVX8 xenografts. CONCLUSIONS: Downregulation/inactivation of HUWE1 may increase c-MYC expression and proliferation in primary-CC-cell-lines. GS-626510 may represent a novel, potentially highly effective therapeutic agent against CC overexpressing c-MYC and/or harboring HUWE1 mutations. Clinical studies with BET inhibitor in CC-patients harboring radiation/chemotherapy-resistant disease are warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bonazzoli E, Bellone S, Zammataro L, et al. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecol Oncol. 2020. PMID: 32600791. doi:10.1016/j.ygyno.2020.06.484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。